Kathryn M. Baker
Chairman of the Board, Kathryn M. Baker has 30 years of business experience in a broad range of industries and roles. She currently serves on the Executive Board of the Central Bank of Norway (Norges Bank), where she is also a member of the audit and ownership committees. Other current board positions include Chairman of Catena Media Plc and board member of Akastor, Sevan Marine and DOF. Ms. Baker also serves on the European Advisory Boards of the Tuck School of Business and DLA Piper Norway and leads the Ethics Committee of the Norwegian Private Equity and Venture Capital Association (NVCA), where she previously served as Chairman. Ms. Baker was a partner at the Norwegian private equity firm Reiten & Co for 15 years. Prior to that, she was a management consultant at McKinsey and Company in Oslo and a financial analyst at Morgan Stanley in New York. Ms. Baker holds a bachelor degree in Economics from Wellesley College and an MBA from the Amos Tuck School of Business at Dartmouth College.
Johan Reinsli has been a board member in Navamedic since March 2007, and has from 2008 until January 2017 held the position as Chairman of the Board. Mr Reinsli is a graduate from Handelsakademiet, Oslo, Norway and has broad international management experience from the banking and finance sector. Previous executive positions include EVP at DnB NOR Kort, Head of Northern Europe at Europay International SA and CEO at Europrocessing International ASA, a company founded by Mr. Reinsli and colleagues. During his career Mr. Reinsli has been completing M&A activities in a number of EU and neighbouring countries. Mr Reinsli has broad international background from various board assignements, and currently works as an independent advisor and board member. Mr Reinsli holds indirectly 244,400 shares in the Company.
Jostein Davidsen has been a board member in Navamedic since January 2017.Jostein brings more than 30 years of experience from the international pharmaceuticals industry, most recently serving as the Chief Executive Officer of the Acino Pharmaceuticals in Switzerland.
He previous founded NYCOMED Russia – CIS, that become one of the top leaders on the Russian - CIS pharmaceutical markets, which grew to over 1500 employees including local manufacturing in 2011 before Nycomed Pharma was acquired by Takeda Pharmaceuticals.
He served after the transaction as a Corporate Officer and the Head of the Emerging Markets at Takeda Pharmaceuticals International based in Zurich Switzerland. He was during this time named the world’s second most influential pharma-industry leader in Emerging Markets by Scrip (the pharmaceutical international news journal).
Davidsen studied Business and Administration at Handelsakademiet in Oslo and have completed several Executive Management Programs and Board learning program at IMD, Lausanne Switzerland.
Svein Erik Nicolaysen
Elected Director of Navamedic in August 2009. Mr Nicolaysen currently holds the position as CEO of the investment company Intersys Norge AS, a part of the group that is the largest shareholders in Navamedic ASA. He is an authorised accountant with accounting practice from Arthur Andersen and Vesterålen-Revisjon AS. From 1998 through 2008, Mr. Nicolaysen was the CEO of the company Vesterålen Naturprodukter AS and Nordic Sales Group AS, companies specialising in direct sales and marketing of health care products such as Omega 3 concentrates. After these companies were sold to Ferrosan AS (DK), Mr Nicolaysen was a member of the Management Board in Ferrosan AS until the end of 2008. Mr Nicolaysen holds 50.000 shares in the Company.
More than More than 30 years commercial experiences from international Pharmaceutical and Diagnostic companies. Has been responsible for building up international business with subsidiaries in countries like USA, China and many European countries. Was part of top management of Axis, and later Axis –Shield plc until acquired in 2011. Last years been CEO and COO in Genetic Analysis as.
Dr. Huaizheng Peng is a General Manager of China Medical System Holdings, a speciality pharmaceutical company listed on the Hong Kong Stock Exchange. He is in charge of international operations in the Company. Dr Peng received his
Bachelor´s degree in medicine from Hunan Medical College, Hunan province, China and subsequently obtained a Master´s degree in medicine from Hunan Medical College. Dr Peng was awarded his PhD in molecular pathology from University College London (UCL) Medical School and subsequently practiced as a clinical lecturer there.